Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) fell 2.9% during trading on Thursday . The stock traded as low as $16.91 and last traded at $16.91. 43,480 shares traded hands during trading, a decline of 90% from the average session volume of 418,549 shares. The stock had previously closed at $17.42.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on BCAX. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a "buy" rating and a $48.00 price target for the company. Morgan Stanley began coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price objective on the stock. RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a report on Tuesday, November 5th. Finally, HC Wainwright initiated coverage on Bicara Therapeutics in a research note on Friday, December 6th. They set a "buy" rating and a $42.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Bicara Therapeutics has a consensus rating of "Buy" and a consensus target price of $43.00.
Get Our Latest Research Report on Bicara Therapeutics
Bicara Therapeutics Stock Down 2.9 %
The stock has a fifty day moving average price of $20.33.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.
Hedge Funds Weigh In On Bicara Therapeutics
Hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $177,169,000. FMR LLC bought a new stake in Bicara Therapeutics in the third quarter valued at $57,913,000. Braidwell LP acquired a new position in shares of Bicara Therapeutics during the third quarter valued at about $42,219,000. Janus Henderson Group PLC bought a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $30,329,000. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at about $21,225,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
